Latest News and Press Releases

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...

HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant...

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira...

HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira’s...

HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA sequence illustrates versatility and potential of RNA...

HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continuesStrong data from Bentrio® NASAR study reinforces its therapeutic benefit for...

HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal...

Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and:Peptide-based platform for extrahepatic deliveryThe...

Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) --Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture process enters decisive phasePartnering...

HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergensCOVAMID trial with Bentrio in...